-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5

Benzinga·08/28/2026 10:50:43
Listen to the news
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.